Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy.
- Author:
Chun-meng WANG
1
;
Ying-qiang SHI
;
Yan-wei YE
;
Hong FU
;
Guang-fa ZHAO
;
Ye ZHOU
;
Chun-yan DU
;
Rui-zeng DONG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; administration & dosage; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; drug therapy; surgery; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; administration & dosage; Prognosis; Pyrimidines; administration & dosage; Retrospective Studies; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2009;12(2):155-158
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the role of surgery and its long-term outcome in patients with advanced gastrointestinal stromal tumor(GIST) treated with imatinib preoperatively.
METHODSThirteen patients receiving imatinib therapy preoperatively, were retrospectively assessed for completeness of surgical resection and for disease-free and overall survival after resection.
RESULTSThirteen patients, including 3 patients with locally advanced primary GIST and 10 patients with recurrent or metastatic GIST, underwent surgery after preoperative treatment with imatinib. Complete resections were accomplished in 4 of the 5 responsive disease(RD) patients, and in 1 of the 8 progression disease(PD) patients (38.5%). The progression-free survival(PFS) time for patients with RD and PD were 24.8 months and 2.8 months respectively. The difference of PFS between patients with RD and those with PD was significant(P<0.01). Median overall survival(OS) was not reached in both patients with RD and PD. The difference of OS between patients with RD and those with PD was not significant(P>0.05).
CONCLUSIONSurgical intervention following imatinib is feasible and can be considered for patients with advanced GIST responsive to imatinib.
